SCHEMBL4382205

SCHEMBL4382205

C=CCn1c(C)cc(O)c(Cl)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.51
MEN1 O00255 5/20 0.51
KDM4E B2RXH2 4/20 0.51
HPGD P15428 1/20 0.51
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 2/20 0.49
MITF O75030 1/20 0.49
POLB P06746 1/20 0.49
HTT P42858 1/20 0.49
RECQL P46063 1/20 0.49
MCL1 Q07820 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CYP3A4 P08684 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
TP53 P04637 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2284503 0.79 KMT2A (0.50) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL13442334 0.73 KMT2A (0.47) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL4375863 0.71 POLB (0.62) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL22932562 0.70 NPC1 (0.46) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL4512017 0.69 ALDH1A1 (0.54) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL4389803 0.68 TLR7 (0.40) ALDH1A1SMN1; SMN2LMNAMITFPOLB
SCHEMBL13442336 0.68 KMT2A (0.45) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL11668101 0.68 KDM4E (1.00) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL14128779 0.67 CYP3A4 (0.56) KMT2AMEN1KDM4EHPGDALDH1A1
SCHEMBL2733440 0.67 KDM4E (0.50) KMT2AMEN1KDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 KMT2A 4574/4885MEN1 3919/4885KDM4E 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.